Collegium Pharmaceutical Inc.
Stoughton, MA
- UEI
- DMDLZN7GH8R7
- CAGE
- 6YMG9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 100 Technology Center Dr, Stoughton, MA 02072, USA
- Website
- collegiumpharma.com
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of oxymorphone deterx, an abuse-deterrent, extended-release opioid FO | National Institutes of Health | $472,811 |
SBA capabilities narrative
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being the leader in responsible pain management. For nearly two decades, Collegium has been focused on developing and commercializing new medicines for pain management that reflect our Core Values and our commitment to people suffering from pain, providers and our communities. The result of those efforts is a portfolio of meaningfully differentiated medications to treat moderate to severe pain.
Quick answers
Is Collegium Pharmaceutical Inc. registered in SAM.gov?
Yes. Collegium Pharmaceutical Inc.'s SAM.gov registration is active through April 1, 2027.
What is Collegium Pharmaceutical Inc.'s CAGE code?
Collegium Pharmaceutical Inc.'s CAGE code is 6YMG9, and its Unique Entity ID (UEI) is DMDLZN7GH8R7.
Which contract vehicles does Collegium Pharmaceutical Inc. hold?
Collegium Pharmaceutical Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Collegium Pharmaceutical Inc.'s most recent federal award?
Collegium Pharmaceutical Inc.'s most recent federal grant award is Development of oxymorphone deterx, an abuse-deterrent, extended-release opioid FO (R44DA037956), from National Institutes of Health, on September 1, 2014.
On GovTribe
See Collegium Pharmaceutical Inc.'s full federal record
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors